538

POPULATION SCREENING FOR LYNCH SYNDROME: INSIGHTS FROM THE ALL OF US RESEARCH PROGRAM

Date
May 19, 2024

Background: Lynch Syndrome (LS) is a common inherited cancer syndrome which is estimated to affect 1 in 279 individuals. In the US, about 1 million individuals have LS, many of whom remain undiagnosed. The CDC recommends population screening for LS, classified as a Tier 1 condition, due to established guidelines for cancer prevention and early detection in individuals with pathogenic germline variants linked to LS.

Methods: We conducted an interim cross-sectional analysis of 2018-2022 data from the All of Us (AOU) Research Program to evaluate LS population screening. This longitudinal cohort study aims to recruit 1 million diverse Americans aged 18+, gathering participant surveys, electronic health records, and biospecimens for genetic condition analysis. We aimed to identify LS carriers with pathogenic or likely pathogenic (P/LP) variants in the MLH1, MSH2, MSH6, and PMS2 genes. We examined demographic data and personal and family cancer histories, stratifying results by genotype and comparing LS carriers with non-LS carriers. LS-related cancers included colorectal (CRC) and endometrial cancers (EC) as well as stomach, small intestine, ovarian, hepatobiliary tract, urinary/bladder/kidney, and pancreatic cancer.

Results: In our analysis of 217,872 individuals, 645 (0.3%) had P/LP variants: 63 (10%) in MLH1, 55 (9%) in MSH2, 212 (33%) in MSH6, and 316 (49%) in PMS2. Among those with available medical records (n=163,002), 476 LS carriers were identified. Of these, 284 (59.7%) were female with median age of 57 years, 65% self-identified as White; these demographics were similar to non-LS carriers. 18% with LS had at least one LS-related cancer, versus 4% of non-carriers (p<0.01). The most common cancers in carriers were CRC at 9.9% (versus 1.2% in non-carriers, p<0.01) and EC at 5.3% (versus 0.5% in non-carriers, p<0.01). Presence of other, non-LS cancers were similar between carriers and non-carriers (9.5% vs 11%, p=NS). The impact of carrier status on age of LS-related cancer presentation and gene-specific results are shown in Figures 1a&b. 73% of LS carriers were cancer-free compared to 85% of non-carriers (p<0.01). Absence of personal and family cancer history was noted in 67% of LS carriers.

Conclusion: Our findings indicate that population-based germline testing for LS may identify up to 67% of carriers who might otherwise go unrecognized if testing was limited to those with personal or family history of cancer. Similar to previous reports, the prevalence of LS was 1 in 338 where P/LP variants in the less penetrant genes MSH6 and PMS2 were more common than previously reported. This underscores the potential importance of population-level genetic screening to optimize identification of LS and additional studies are needed to assess the impact on preventative screening.
Figure 1. Cumulative Distribution of LS-associated Cancers, by Age at Presentation. (a) Comparison between LS-carriers and non-LS carriers; (b) Comparison between gene-specific LS carriers and non-LS carriers.

Figure 1. Cumulative Distribution of LS-associated Cancers, by Age at Presentation. (a) Comparison between LS-carriers and non-LS carriers; (b) Comparison between gene-specific LS carriers and non-LS carriers.

Presenter

Speakers

Speaker Image for Chin Hur
Massachusetts General Hospital
Speaker Image for Fay Kastrinos
Columbia University

Tracks

Related Products

Thumbnail for AGA Diet Management in GI Cancers
AGA Diet Management in GI Cancers
The impact of diets on GI cancers has been well documented, however just recently we are understanding how diet impacts tumorigenesis…
Thumbnail for IDENTIFYING NOVEL RISK ALLELES FOR CELIAC DISEASE IN "ALL OF US"
IDENTIFYING NOVEL RISK ALLELES FOR CELIAC DISEASE IN "ALL OF US"
It is well known of the requirement of HLA-DQ2/8 for developing CeD, but only 3% of DQ2/8 carriers have CeD. Therefore, a systemic approach is required to improve the clinical utility of genetic testing and providing a better genetic risk stratification…
Thumbnail for NEXT GENERATION SEQUENCING BASED HIGH RESOLUTION HLA TYPING REVEALED MORE THAN HLA-DQ2/8 IN CELIAC DISEASE
NEXT GENERATION SEQUENCING BASED HIGH RESOLUTION HLA TYPING REVEALED MORE THAN HLA-DQ2/8 IN CELIAC DISEASE
BACKGROUND: Marine omega-3 fatty acids (MO3FAs) - which include eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) - are fatty acids that have anti-inflammatory properties, reducing C-reactive protein (CRP) and proinflammatory cytokines…